Navigation Links
JCI early table of contents for Jan. 9, 2013
Date:1/9/2013

Small peptide ameliorates autoimmune skin blistering disease in mice

Pemphigus vulgaris is a life-threatening autoimmune skin disease that is occurs when the body's immune system generates antibodies that target proteins in the skin known as desomogleins. Desmogleins help to form the adhesive bonds that hold skin cells together and keep the skin intact. Currently, pemphigus vulgaris is treated by long-term immune suppression; however, this can leave the patient susceptible to infection. In this issue of the Journal of Clinical Investigation, researchers led by Jens Waschke at the Institute of Anatomy and Cell Biology in Munich, Germany, report on a small peptide that blocked antibody recognition of desmogleins. Importantly, the peptide could prevent antibody-mediated skin blistering when applied topically to mice. At the cellular level, the peptide improved cell-cell adhesion and attenuated signaling pathways that are activated by antibody binding. These results suggest that this peptide could serve as a treatment option for pemphigus vulgaris.

TITLE:
Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering

AUTHOR CONTACT:
Jens Waschke
Ludwig-Maximilians-University Munich, Munich, , DEU
Phone: 0049-89-5160-4811; Fax: 0049-89-5160-4802; E-mail: jens.waschke@med.uni-muenchen.de

View this article at: http://www.jci.org/articles/view/60139?key=b333192372ea9937c9be


A new treatment for kidney disease-associated heart failure?

Chronic kidney disease (CKD) patients frequently suffer from mineral bone disorder, which causes vascular calcification and, eventually, chronic heart failure. Similar to patients with CKD, mice with low levels of the protein klotho (klotho hypomorphic mice) also develop vascular calcification and have shorter life spans compared to normal mice. In this issue of the Journal of Clinical Investigation, Florian Lang and colleagues at the University of Tbingen in Germany, found that treatment with the mineralocorticoid receptor antagonist spironolactone reduced vascular calcification in klotho hypomorphic mice and increased their life span. In a companion Attending Physician article, Darryl Quarles of the University of Tennessee discusses the implications of these findings for the treatment of CKD patients.

TITLE:
Spironolactone-sensitive vascular calcification and Pit-1-dependent osteoblastic differentiation in klotho-hypomorphic mice

AUTHOR CONTACT:
Florian Lang
Dept. of Physiology, Tuebingen, NULL, DEU
Phone: +4970712972194; Fax: +497071295618; E-mail: florian.lang@uni-tuebingen.de

View this article at: http://www.jci.org/articles/view/64093?key=3010c850d2f970ad6617

ACCOMPANYING THE ATTENDING PHYSICIAN

TITLE:
Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new

AUTHOR CONTACT:
Darryl Quarles
University of Tennessee Health Science Center, memphis, TN, USA
Phone: 901-448-1459; Fax: 901-448-1188; E-mail: dquarles@uthsc.edu

View this article at: http://www.jci.org/articles/view/67203?key=054ae63743c930253936


New fusion gene contributes to glioblastoma progression

Fusion genes are common chromosomal aberrations in many cancers, and can be used as prognostic markers and drug targets in clinical practice. In this issue of the Journal of Clinical Investigation, researchers led by Matti Annala at Tampere University of Technology in Finland identified a fusion between the FGFR3 and TACC3 genes in human glioblastoma samples. The protein produced by this fusion gene promoted tumor growth and progression in a mouse model of glioblastoma, while increased expression of either of the normal genes did not alter tumor progression. Ivan Babic and Paul Mischel of the University of California, San Diego, explain in the accompanying commentary that it remains unclear how this fusion protein mediates tumorigenesis.

TITLE:
The tumorigenic fusion FGFR3-TACC3 escapes miR-99a regulation in glioblastoma

AUTHOR CONTACT:
Matti Annala
Tampere University of Technology, Tampere, FIN
Phone: +358415079885; E-mail: matti.annala@tut.fi

View this article at: http://www.jci.org/articles/view/67144?key=b644a26bcc8a516cd41d

ACCOMPANYING COMMENTARY

TITLE:
Multiple functions of a glioblastoma fusion oncogene

AUTHOR CONTACT:
Paul Mischel
UCSD, La Jolla, CA, USA
Phone: (858) 534-6080; Fax: ; E-mail: pmischel@ucsd.edu

View this article at: http://www.jci.org/articles/view/67658?key=0186fce1cd2ddde6082f


ALSO IN THIS ISSUE

TITLE:
Type 1 diabetes patients exhibit altered cerebral metabolism during hypoglycemia

AUTHOR CONTACT:
Bastiaan de Galan
Radboud University Nijmegen Medical Centre, Nijmegen, UNK, NLD
Phone: +31243618819; Fax: +31243541734; E-mail: b.degalan@aig.umcn.nl

View this article at: http://www.jci.org/articles/view/62742?key=9b86666385df6bd2593b

TITLE:
Regulation of dendritic cell activation by microRNA let-7c and BLIMP1

AUTHOR CONTACT:
Betty Diamond
The Feinstein Institute for Medical Research, Manhasset, NY, USA
Phone: 516-562-3830; Fax: 516-562-2953; E-mail: bdiamond@nshs.edu

View this article at: http://www.jci.org/articles/view/64712?key=6599e97537112226049c

TITLE:
Liver acid sphingomyelinase inhibits growth of metastatic colon cancer

AUTHOR CONTACT:
Yosuke Osawa
Gifu University Graduate School of Medicine, Gifu, JPN
Phone: 81-58-230-6217; Fax: 81-58-230-6218; E-mail: osawa-gif@umin.ac.jp

View this article at: http://www.jci.org/articles/view/65188?key=4dc45a19d2e16fb3b7c9

TITLE:
Specialized role of migratory dendritic cells in peripheral tolerance induction

AUTHOR CONTACT:
Juliana Idoyaga
The Rockefeller University, New York, NY, USA
Phone: 212-327-7863; Fax: 212-327-8875; E-mail: ijuliana@rockefeller.edu

View this article at: http://www.jci.org/articles/view/65260?key=843f605de298ce5048b3


'/>"/>

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. New Stool Test Might Aid in Early Detection of Colon Cancer
2. An Early Start for Your Child with Autism
3. Early Study Finds Some Promise for Lung Cancer Vaccine
4. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
5. JCI early table of contents for April 9, 2012
6. Eye Tremors May Aid Early Diagnosis of Parkinsons: Study
7. Nearly 1 in 4 grandparents store prescription medicines where children can easily find them
8. First contact: Early intervention key in diagnosis and treatment of serious mental illness
9. Brain Tumor Vaccine Shows Promise in Early Trial
10. Role of Screening, Monitoring in Early Kidney Disease Unclear
11. Detecting malaria early to save lives: New optical technique promises rapid and accurate diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart ... at its new location in the Exchange Furniture Mall at 112 Vilseck Road in ... 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet general dentists ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification Program ... to announce the launch of the GFCP Scoop in response to ... purpose of the GFCP Scoop site is to keep the gluten-free ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
Breaking Medicine Technology: